|
|||||
|
|
| 恩替卡韦和阿德福韦酯对HBeAg阳性慢性乙型肝炎疗效的Meta分析 | |
| 引用本文： | 赵攀,唐一平,赵沐缙,祁京,柳伟伟. 恩替卡韦和阿德福韦酯对HBeAg阳性慢性乙型肝炎疗效的Meta分析[J]. 疑难病杂志, 2011, 10(1): 23-26. DOI: 10.3969/j.issn.1671-6450.2011.01.010 |
| 作者姓名： | 赵攀 唐一平 赵沐缙 祁京 柳伟伟 |
| 作者单位： | 1. 解放军第302医院病毒性肝炎研究室,北京,100039 2. 首都医科大学附属北京安贞医院,北京,100029 3. 解放军总后勤部第三门诊部,北京,100039 |
| 摘 要： | 目的探讨恩替卡韦与阿德福韦酯对核苷初治HBeAg阳性慢性乙型肝炎患者的疗效。方法检索2000年1月—2010年5月公开发表的有关恩替卡韦(剂量0.5mg/d)与阿德福韦酯(剂量10 mg/d)治疗HBeAg阳性的核苷初治的慢性乙型肝炎(疗程≥48周)的随机对照临床研究。采用x~2检验分析研究间的异质性,以相对危险度为疗效分析统计量进行合并分析并绘制森林图。疗效判定指标包括血清HBV DNA检测不到(阴转)、血清ALT复常、血清HBeAg阴转、抗-HBe血清转换和药物不良反应。结果最终纳入1篇英文文献,3篇中文文献,纳入文献的总体质量较高(Jadad评分2～4分)。Meta分析结果显示,恩替卡韦治疗组血清HBV DNA阴转率、血清ALT复常率高于阿德福韦酯组(均P<0.01),而2组血清HBeAg转阴率、血清抗-HBe转换率和不良反应发生率的差异无统计学意义(均P>0.05)。结论恩替卡韦在降低患者血清HBV DNA载量和促使ALT回复正常水平方面优于阿德福韦酯,但在血清HBeAg转阴率、血清抗-HBe转换率及不良反应方面两者相似。 |
| 关 键 词： | 乙型肝炎,慢性 核苷类似物 HBeAg阳性 核苷初治 |
Meta analysis of entecavir and adefovir on chronic hepatitis B with HBeAg positive |
|
| ZHAO Pan,TANG Yi-ping,ZHAO Mu-jin,et al.. Meta analysis of entecavir and adefovir on chronic hepatitis B with HBeAg positive[J]. Journal of Difficult and Complicated Cases, 2011, 10(1): 23-26. DOI: 10.3969/j.issn.1671-6450.2011.01.010 | |
| Authors: | ZHAO Pan TANG Yi-ping ZHAO Mu-jin et al. |
| Affiliation: | ZHAO Pan~*,TANG Yi-ping,ZHAO Mu-jin,et al.*Viral Hepatitis Research Laboratory,The PLA 302 Hospital,Beijing 100039,China |
| Abstract: | Objective To evaluate the therapeutic efficacy between entecavir and adefovir dipivoxil in chronic hepatitis B patients with HBeAg positive.Methods Reviewed the Chinese and English articles(randomized controlled clinical trials) about comparison of efficacy between entecavir and adefovir dipivoxil in chronic hepatitis B patients with HBeAg positive, which searched from January 2000 to May 2010.The dosages of entecavir and adefovir dipivoxil were respectively 0.5mg/d and 10mg/d,and treatment course lasted ov... |
| Keywords: | Hepatitis B chronic Nucleoside and nucleotide analogues HBeAg positive Nucleotide naive |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ | |